8 / 20
Page 41
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Clin Trial
ISSN: 2167-0870 JCTR, an open access journal
Global Pharmacovigilance 2017
July 06-07, 2017
JULY 06-07, 2017 KUALA LUMPUR, MALAYSIA
8
TH
GLOBAL
Pharmacovigilance &
Drug Safety Summit
J Clin Trial 2017, 7:4 (Suppl)
DOI: 10.4172/2167-0870-C1-017
Potential nephroprotective effects of L-carnitine against drug-induced nephropathy: A review of
literature
Atefeh Jafari
Guilan University of Medical Sciences, Iran
D
rug-induced nephrotoxicity (DIN) has been reported with a great number of medications. The significance of DIN lies
in its contribution to approximately 20% of the hospital admissions. Various therapeutic agents such as L-carnitine have
been proposed to reduce DIN. Antioxidant, anti-inflammatory and anti-apoptotic effects of L-carnitine make it a candidate for
nephro-protection against DIN. These benefits of L-carnitine necessitated the current review. The present review covered all
clinical and animal research published on the concept of nephroprotective effects of L-carnitine against DIN. L-carnitine was
significantly effective in amelioration of DIN in
in vitro
and animal studies, especially against cisplatin-induced renal damage.
Inhibitionof reactive oxygen species generation, lipidperoxidation, apoptosis,matrix remodeling, anti-inflammatoryproperties,
and improvement in carnitine deficiency has been suggested as probable nephroprotective mechanisms of L-carnitine. In
spite of the evidence support the nephroprotective effect of L-carnitine, the main problems in this area are the inadequacy of
reliable studies in humans and difficulty of translating the experimental results into clinical practice. Use of L-carnitine as a
prophylactic nephroprotective agent for nephrotoxic therapies is rarely possible except for contrast-induced nephrotoxicity.
Research on these nephroprotective effects in human population seems essential before generalization the results to human
subjects. The possible impact of L-carnitine on the therapeutic efficacy of nephrotoxic agents such as calcineurin inhibitors
and aminoglycosides remain as a question for further studies. Development of validated early biomarkers to detect DIN may
provide the opportunity to use prophylactic nephroprotective agents at the golden time.
atf.jafari@gmail.com